S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:GRTS

Gritstone Oncology Competitors

$13.59
-0.25 (-1.81 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.98
Now: $13.59
$14.12
50-Day Range
$5.77
MA: $15.75
$27.11
52-Week Range
$2.54
Now: $13.59
$35.20
Volume587,164 shs
Average Volume4.49 million shs
Market Capitalization$513.21 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2

Competitors

Gritstone Oncology (NASDAQ:GRTS) Vs. KYMR, BCRX, BLUE, VCEL, SRRK, and OCGN

Should you be buying GRTS stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Gritstone Oncology, including Kymera Therapeutics (KYMR), BioCryst Pharmaceuticals (BCRX), bluebird bio (BLUE), Vericel (VCEL), Scholar Rock (SRRK), and Ocugen (OCGN).

Kymera Therapeutics (NASDAQ:KYMR) and Gritstone Oncology (NASDAQ:GRTS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Kymera Therapeutics and Gritstone Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kymera TherapeuticsN/AN/AN/A
Gritstone Oncology-2,962.52%-101.31%-68.78%

Institutional and Insider Ownership

37.8% of Kymera Therapeutics shares are held by institutional investors. Comparatively, 59.0% of Gritstone Oncology shares are held by institutional investors. 38.0% of Gritstone Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Kymera Therapeutics and Gritstone Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kymera Therapeutics02402.67
Gritstone Oncology10202.33

Kymera Therapeutics presently has a consensus price target of $50.3333, suggesting a potential upside of 9.75%. Gritstone Oncology has a consensus price target of $22.3333, suggesting a potential upside of 64.34%. Given Gritstone Oncology's higher probable upside, analysts clearly believe Gritstone Oncology is more favorable than Kymera Therapeutics.

Earnings & Valuation

This table compares Kymera Therapeutics and Gritstone Oncology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kymera TherapeuticsN/AN/AN/AN/AN/A
Gritstone Oncology$4.36 million117.71$-94,430,000.00($2.81)-4.84

Kymera Therapeutics has higher earnings, but lower revenue than Gritstone Oncology.

Summary

Kymera Therapeutics beats Gritstone Oncology on 5 of the 9 factors compared between the two stocks.

Gritstone Oncology (NASDAQ:GRTS) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Gritstone Oncology and BioCryst Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gritstone Oncology-2,962.52%-101.31%-68.78%
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%

Institutional & Insider Ownership

59.0% of Gritstone Oncology shares are owned by institutional investors. Comparatively, 72.0% of BioCryst Pharmaceuticals shares are owned by institutional investors. 38.0% of Gritstone Oncology shares are owned by insiders. Comparatively, 4.3% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Gritstone Oncology has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 3.03, suggesting that its share price is 203% more volatile than the S&P 500.

Valuation & Earnings

This table compares Gritstone Oncology and BioCryst Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gritstone Oncology$4.36 million117.71$-94,430,000.00($2.81)-4.84
BioCryst Pharmaceuticals$48.83 million39.70$-108,900,000.00($0.94)-11.62

Gritstone Oncology has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Gritstone Oncology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Gritstone Oncology and BioCryst Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gritstone Oncology10202.33
BioCryst Pharmaceuticals03802.73

Gritstone Oncology presently has a consensus target price of $22.3333, suggesting a potential upside of 64.34%. BioCryst Pharmaceuticals has a consensus target price of $11.3750, suggesting a potential upside of 4.17%. Given Gritstone Oncology's higher probable upside, equities analysts clearly believe Gritstone Oncology is more favorable than BioCryst Pharmaceuticals.

Gritstone Oncology (NASDAQ:GRTS) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Institutional and Insider Ownership

59.0% of Gritstone Oncology shares are owned by institutional investors. Comparatively, 94.3% of bluebird bio shares are owned by institutional investors. 38.0% of Gritstone Oncology shares are owned by company insiders. Comparatively, 3.6% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Gritstone Oncology and bluebird bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gritstone Oncology10202.33
bluebird bio013402.24

Gritstone Oncology presently has a consensus price target of $22.3333, indicating a potential upside of 64.34%. bluebird bio has a consensus price target of $68.4667, indicating a potential upside of 145.05%. Given bluebird bio's higher possible upside, analysts plainly believe bluebird bio is more favorable than Gritstone Oncology.

Profitability

This table compares Gritstone Oncology and bluebird bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gritstone Oncology-2,962.52%-101.31%-68.78%
bluebird bio-256.84%-45.78%-35.14%

Earnings and Valuation

This table compares Gritstone Oncology and bluebird bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gritstone Oncology$4.36 million117.71$-94,430,000.00($2.81)-4.84
bluebird bio$44.67 million42.00$-789,610,000.00($14.31)-1.95

Gritstone Oncology has higher earnings, but lower revenue than bluebird bio. Gritstone Oncology is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Gritstone Oncology has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500.

Summary

bluebird bio beats Gritstone Oncology on 9 of the 14 factors compared between the two stocks.

Gritstone Oncology (NASDAQ:GRTS) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Gritstone Oncology and Vericel, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gritstone Oncology10202.33
Vericel02602.75

Gritstone Oncology currently has a consensus target price of $22.3333, indicating a potential upside of 64.34%. Vericel has a consensus target price of $49.00, indicating a potential upside of 21.26%. Given Gritstone Oncology's higher probable upside, analysts clearly believe Gritstone Oncology is more favorable than Vericel.

Valuation and Earnings

This table compares Gritstone Oncology and Vericel's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gritstone Oncology$4.36 million117.71$-94,430,000.00($2.81)-4.84
Vericel$117.85 million15.76$-9,660,000.00$0.18224.50

Vericel has higher revenue and earnings than Gritstone Oncology. Gritstone Oncology is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Gritstone Oncology has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Vericel has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500.

Insider & Institutional Ownership

59.0% of Gritstone Oncology shares are owned by institutional investors. Comparatively, 93.1% of Vericel shares are owned by institutional investors. 38.0% of Gritstone Oncology shares are owned by company insiders. Comparatively, 4.3% of Vericel shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Gritstone Oncology and Vericel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gritstone Oncology-2,962.52%-101.31%-68.78%
Vericel0.12%0.13%0.10%

Summary

Vericel beats Gritstone Oncology on 10 of the 14 factors compared between the two stocks.

Gritstone Oncology (NASDAQ:GRTS) and Scholar Rock (NASDAQ:SRRK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Profitability

This table compares Gritstone Oncology and Scholar Rock's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gritstone Oncology-2,962.52%-101.31%-68.78%
Scholar Rock-365.84%-80.16%-41.33%

Volatility and Risk

Gritstone Oncology has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Gritstone Oncology and Scholar Rock, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gritstone Oncology10202.33
Scholar Rock00503.00

Gritstone Oncology presently has a consensus target price of $22.3333, indicating a potential upside of 64.34%. Scholar Rock has a consensus target price of $61.60, indicating a potential upside of 21.74%. Given Gritstone Oncology's higher probable upside, equities analysts plainly believe Gritstone Oncology is more favorable than Scholar Rock.

Institutional and Insider Ownership

59.0% of Gritstone Oncology shares are held by institutional investors. Comparatively, 61.9% of Scholar Rock shares are held by institutional investors. 38.0% of Gritstone Oncology shares are held by insiders. Comparatively, 24.6% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Gritstone Oncology and Scholar Rock's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gritstone Oncology$4.36 million117.71$-94,430,000.00($2.81)-4.84
Scholar Rock$20.49 million83.07$-51,000,000.00($1.85)-27.35

Scholar Rock has higher revenue and earnings than Gritstone Oncology. Scholar Rock is trading at a lower price-to-earnings ratio than Gritstone Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Scholar Rock beats Gritstone Oncology on 9 of the 14 factors compared between the two stocks.

Gritstone Oncology (NASDAQ:GRTS) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability.

Insider and Institutional Ownership

59.0% of Gritstone Oncology shares are owned by institutional investors. Comparatively, 8.5% of Ocugen shares are owned by institutional investors. 38.0% of Gritstone Oncology shares are owned by insiders. Comparatively, 3.5% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and target prices for Gritstone Oncology and Ocugen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gritstone Oncology10202.33
Ocugen01302.75

Gritstone Oncology presently has a consensus target price of $22.3333, suggesting a potential upside of 64.34%. Ocugen has a consensus target price of $4.80, suggesting a potential downside of 46.49%. Given Gritstone Oncology's higher possible upside, equities analysts clearly believe Gritstone Oncology is more favorable than Ocugen.

Profitability

This table compares Gritstone Oncology and Ocugen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gritstone Oncology-2,962.52%-101.31%-68.78%
OcugenN/A-47.72%-30.78%

Earnings and Valuation

This table compares Gritstone Oncology and Ocugen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gritstone Oncology$4.36 million117.71$-94,430,000.00($2.81)-4.84
OcugenN/AN/A$-20,240,000.00($1.48)-6.06

Ocugen has lower revenue, but higher earnings than Gritstone Oncology. Ocugen is trading at a lower price-to-earnings ratio than Gritstone Oncology, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gritstone Oncology has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.56, indicating that its stock price is 256% more volatile than the S&P 500.

Summary

Ocugen beats Gritstone Oncology on 8 of the 13 factors compared between the two stocks.


Gritstone Oncology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86-1.9%$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92-8.7%$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94-5.0%$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41-4.2%$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60-1.7%$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97-16.6%$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07-2.5%$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23-0.3%$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65-16.2%$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29-0.8%$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30-1.3%$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21-2.4%$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42-8.4%$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89-0.4%$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25-1.0%$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08-7.0%$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62-9.4%$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25-1.2%$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18-0.3%$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37-3.2%$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96-3.1%$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56-9.9%$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25-1.6%$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43-2.7%$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40-7.7%$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73-8.0%$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40-10.4%$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.